M&A Deal Summary |
|
|---|---|
| Date | 2015-12-11 |
| Target | Crealta Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Horizon Therapeutics |
| Sellers(s) | GTCR |
| Deal Type | Add-on Acquisition |
| Deal Value | 510M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2005 |
| Sector | Life Science |
| Employees | 2,100 |
| Revenue | 3.2B USD (2021) |
Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Therapeutics was founded in 2005 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 11 |
| Sector (Life Science) | 5 of 11 |
| Type (Add-on Acquisition) | 3 of 7 |
| State (Wisconsin) | 1 of 1 |
| Country (United States) | 5 of 9 |
| Year (2015) | 2 of 2 |
| Size (of disclosed) | 5 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-04-03 |
Hyperion Therapeutics
Brisbane, California, United States Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. |
Buy | $1.1B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-05-19 |
Boehringer Ingelheim - Interferon Gamma-1b
Germany Boehringer Ingelheim - Interferon Gamma-1b comprises rights to manufacture the pharmaceutical Interferon Gamma-1b, which Boehringer Ingelheim commercializes under the trade names IMUKIN, IMUKINE, IMMUKIN and IMMUKINE in an estimated 30 countries primarily in Europe and the Middle East. |
Buy | €25M |
| Category | Private Equity Firm |
|---|---|
| Founded | 1980 |
| PE ASSETS | 15.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
GTCR is a private equity firm that typically partners with management when pursuing acquisitions. The Firm looks to grow companies through build-on acquisitions, consolidations, and internal growth. GTCR will consider both equity and mezzanine capital commitments and concentrates its investment activity in consumer products & services, healthcare services, outsourced business services, technology, transaction processing, and pharma/medical products. GTCR was formed in 1980 and is based in Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 56 of 84 |
| Sector (Life Science) | 4 of 5 |
| Type (Add-on Acquisition) | 30 of 40 |
| State (Wisconsin) | 2 of 2 |
| Country (United States) | 54 of 81 |
| Year (2015) | 9 of 9 |
| Size (of disclosed) | 24 of 33 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-11-30 |
Park Place Technologies
Cleveland, Ohio, United States Park Place Technologies is a third-party maintenance (TPM) provider that offers organizations an alternative to post-warranty storage, server and networking hardware maintenance and support in the data center. Park Place Technologies supports EMC, Dell, IBM, Cisco, Hitachi, NetApp, HP, Sun/Oracle and other data center hardware equipment in over 70 countries. Park Place Technologies was founded in 1991 and is based in Cleveland, Ohio. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-01-06 |
Onvoy Voice Services
Minneapolis, Minnesota, United States Onvoy Voice Services is a provider of telecommunications solutions to wireless carriers and Voice over Internet Protocol service providers. |
Buy | - |
